Avalo Therapeutics Inc Financials
Avalo Therapeutics Inc (AVTX) reported $59K in revenue for fiscal year 2025, down 86.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Avalo’s cash-funded R&D burn dominates its economics, with financing rather than revenue shaping the balance sheet.
The liquidity picture is weaker than the 8.1x current ratio suggests because current liabilities are only$12.9M . Even after$14.6M of financing in FY2025, cash ended at only$15.9M , showing the prior year’s cushion was externally built rather than earned from operations.
This is operating more like a development-stage balance sheet than a commercial one: FY2025 revenue was just
The balance sheet is light on obligations: total liabilities were
Financial Health Signals
Avalo Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Avalo Therapeutics Inc scores 13.48, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.1B) relative to total liabilities ($33.4M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Avalo Therapeutics Inc passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Avalo Therapeutics Inc reported a net loss of $78.3M while operations used $51.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Avalo Therapeutics Inc generated $59K in revenue in fiscal year 2025. This represents a decrease of 86.6% from the prior year.
Avalo Therapeutics Inc's EBITDA was -$72.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 6.2% from the prior year.
Avalo Therapeutics Inc reported -$78.3M in net income in fiscal year 2025. This represents a decrease of 122.8% from the prior year.
Avalo Therapeutics Inc earned -$5.84 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
Avalo Therapeutics Inc held $15.9M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Avalo Therapeutics Inc's ROE was -94.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 67.8 percentage points from the prior year.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Avalo Therapeutics Inc invested $50.1M in research and development in fiscal year 2025. This represents an increase of 105.0% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
AVTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $59K-86.6% | $441K-77.1% | $1.9M-89.3% | $18.1M+234.4% | $5.4M-19.4% | $6.7M-0.8% | $6.8M-4.0% | $7.0M-74.7% | $27.8M+2312.3% | $1.2M | $0 | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | $1.3M-62.6% | $3.4M+130.3% | $1.5M+397.0% | $300K+153.0% | -$567K-117.4% | $3.3M+413.0% | $636K | $0 | $0 | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | $640K-95.6% | $14.6M+274.1% | $3.9M-38.9% | $6.4M | N/A | $3.8M-86.1% | $27.2M+2257.1% | $1.2M | $0 | N/A | N/A |
| R&D Expenses | N/A | $50.1M+105.0% | $24.4M+77.3% | $13.8M-56.0% | $31.3M-47.7% | $59.8M+85.9% | $32.2M+173.7% | $11.8M+103.3% | $5.8M+32.3% | $4.4M-56.9% | $10.1M+54.1% | $6.6M-46.2% | $12.2M+37.3% | $8.9M |
| SG&A Expenses | N/A | $22.9M+32.8% | $17.2M+67.4% | $10.3M-50.3% | $20.7M-16.0% | $24.7M+41.6% | $17.4M+72.1% | $10.1M-3.7% | $10.5M+32.4% | $7.9M+12.1% | $7.1M+60.2% | $4.4M-9.3% | $4.9M+21.3% | $4.0M |
| Operating Income | N/A | -$72.9M-6.4% | -$68.5M-150.5% | -$27.4M+26.9% | -$37.4M+54.4% | -$82.1M-12.8% | -$72.8M-351.4% | -$16.1M+54.4% | -$35.4M-354.7% | $13.9M+186.4% | -$16.1M-46.1% | -$11.0M+35.7% | -$17.1M-32.3% | -$12.9M |
| Income Tax | N/A | $165K+44.7% | $114K+714.3% | $14K-50.0% | $28K+114.3% | -$196K+93.0% | -$2.8M-1096.4% | $280K+666.7% | -$49K-102.5% | $2.0M | $0 | $0 | N/A | N/A |
| Net Income | N/A | -$78.3M-122.8% | -$35.1M-11.4% | -$31.5M+24.3% | -$41.7M+50.6% | -$84.4M-32.9% | -$63.5M-295.1% | -$16.1M+59.9% | -$40.1M-437.4% | $11.9M+172.1% | -$16.5M-57.0% | -$10.5M+34.7% | -$16.1M-23.1% | -$13.0M |
| EPS (Diluted) | — | -$5.84 | -$20.91 | -$113.58 | -$1063.00 | N/A | N/A | N/A | -$1.20-385.7% | $0.42 | -$1.87 | -$4.71 | N/A | N/A |
Not reported in any period shown, so not listed: Interest Expense.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
AVTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $116.5M-22.7% | $150.7M+618.0% | $21.0M-37.1% | $33.4M-58.4% | $80.2M+83.3% | $43.8M+21.2% | $36.1M-48.6% | $70.3M+64.1% | $42.8M+642.0% | $5.8M-73.4% | $21.7M+75.8% | $12.3M | N/A |
| Current Assets | $105.3M-24.2% | $138.9M+1554.4% | $8.4M-48.9% | $16.4M-73.5% | $61.8M+137.8% | $26.0M+46.7% | $17.7M-19.2% | $21.9M+105.5% | $10.7M+88.5% | $5.7M-73.8% | $21.6M+77.8% | $12.2M | N/A |
| Cash & Equivalents | $15.9M-88.2% | $134.5M+1714.5% | $7.4M-43.7% | $13.2M-75.9% | $54.6M+188.5% | $18.9M+424.2% | $3.6M-66.1% | $10.6M+330.6% | $2.5M-51.8% | $5.1M-75.8% | $21.2M+80.2% | $11.7M+243.2% | $3.4M |
| Inventory | N/A | N/A | $0-100.0% | $20K-47.4% | $38K+1166.7% | $3K-85.9% | $21K-93.3% | $318K-16.8% | $382K | $0 | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | $0-100.0% | $1.1M-51.3% | $2.2M+117.3% | $1.0M+21.8% | $822K-72.0% | $2.9M+2115.6% | $132K | N/A | N/A | N/A |
| Goodwill | $10.5M0.0% | $10.5M0.0% | $10.5M-27.1% | $14.4M0.0% | $14.4M0.0% | $14.4M0.0% | $14.4M0.0% | $14.4M+17.2% | $12.3M | $0 | N/A | N/A | N/A |
| Total Liabilities | $33.4M+88.8% | $17.7M+29.3% | $13.7M-69.1% | $44.3M-22.5% | $57.1M+197.7% | $19.2M+27.0% | $15.1M-69.4% | $49.3M+230.1% | $14.9M+168.7% | $5.6M-35.1% | $8.6M-77.8% | $38.6M | N/A |
| Current Liabilities | $12.9M+85.9% | $7.0M+50.7% | $4.6M-79.1% | $22.1M+11.2% | $19.9M+30.6% | $15.2M+25.2% | $12.2M-53.6% | $26.2M+136.4% | $11.1M+157.2% | $4.3M-26.3% | $5.8M+17.1% | $5.0M | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $14.3M | $0 | $0-100.0% | $2.4M-55.7% | $5.3M | N/A |
| Total Equity | $83.0M-37.6% | $133.0M+1721.4% | $7.3M+166.9% | -$10.9M-147.3% | $23.1M-6.0% | $24.6M+17.0% | $21.0M+0.4% | $20.9M-25.0% | $27.9M+13358.6% | $207K-98.4% | $13.1M+149.7% | -$26.3M-47.5% | -$17.8M |
| Retained Earnings | -$448.5M-21.1% | -$370.3M-10.5% | -$335.1M-10.3% | -$303.8M-15.9% | -$262.2M-47.5% | -$177.8M-55.6% | -$114.3M-16.4% | -$98.2M-68.9% | -$58.2M+16.9% | -$70.0M-30.8% | -$53.6M-24.4% | -$43.1M | N/A |
AVTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$68.3M | -$51.5M-4.9% | -$49.1M-59.9% | -$30.7M-14.7% | -$26.8M+62.3% | -$70.9M-74.9% | -$40.5M-111.9% | -$19.1M-511.7% | -$3.1M-124.9% | $12.6M+186.3% | -$14.6M-43.4% | -$10.2M+34.5% | -$15.5M-35.1% | -$11.5M |
| Capital Expenditures | N/A | N/A | N/A | N/A | $95K-15.9% | $113K+79.4% | $63K-76.0% | $262K-53.6% | $564K+2319.8% | $23K-33.1% | $35K+74.6% | $20K+2.5% | $20K-33.4% | $29K |
| Free Cash Flow | N/A | N/A | N/A | N/A | -$26.8M+62.2% | -$71.0M-74.9% | -$40.6M-109.3% | -$19.4M-425.3% | -$3.7M-129.4% | $12.6M+185.9% | -$14.6M-43.4% | -$10.2M+34.5% | -$15.5M-34.9% | -$11.5M |
| Investing Cash Flow | -$315.3M | -$81.7M-23055.1% | $356K+367.7% | -$133K-40.0% | -$95K+15.9% | -$113K-101.0% | $11.1M+2612.9% | -$443K-151.2% | $865K+104.6% | -$18.9M-54116.3% | -$35K-74.6% | -$20K | N/A | N/A |
| Financing Cash Flow | $426.7M | $14.6M-91.7% | $175.8M+602.2% | $25.0M+270.4% | -$14.7M-113.8% | $106.8M+138.4% | $44.8M+256.6% | $12.6M+20.7% | $10.4M+178.4% | $3.7M+362.1% | -$1.4M-107.3% | $19.6M | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
AVTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | 33.3%-47.7pp | 81.0%+8.6pp | 72.4%-23.1pp | 95.5% | N/A | 53.6%-44.1pp | 97.7%-2.3pp | 100.0% | N/A | N/A | N/A |
| Operating Margin | -123601.7% | -15535.6% | -1421.6% | -207.4% | -1521.6% | -1087.4% | -239.1% | -503.4% | 49.9% | -1394.6% | N/A | N/A | N/A |
| Net Margin | -132642.4% | -7965.8% | -1639.5% | -230.8% | -1563.1% | -947.9% | -238.1% | -569.9% | 42.7% | -1428.6% | N/A | N/A | N/A |
| Return on Equity | -94.2%-67.8pp | -26.4%+405.5pp | -431.9% | N/A | -365.6%-107.0pp | -258.5%-182.0pp | -76.5%+115.0pp | -191.6%-234.2pp | 42.6%+7999.8pp | -7957.2%-7877.0pp | -80.2% | N/A | N/A |
| Return on Assets | -67.2%-43.9pp | -23.3%+126.9pp | -150.3%-25.4pp | -124.8%-19.7pp | -105.2%+39.9pp | -145.1%-100.6pp | -44.5%+12.5pp | -57.0%-84.7pp | 27.7%+313.3pp | -285.5%-237.1pp | -48.4%+81.9pp | -130.4% | N/A |
| Current Ratio | 8.14-11.8x | 19.96+18.1x | 1.82+1.1x | 0.74-2.4x | 3.11+1.4x | 1.71+0.3x | 1.46+0.6x | 0.84-0.1x | 0.96-0.4x | 1.31-2.4x | 3.70+1.3x | 2.44 | N/A |
| Debt-to-Equity | 0.40+0.3x | 0.13-1.7x | 1.87 | N/A | 2.48+1.7x | 0.78+0.1x | 0.720.0x | 0.69+0.7x | 0.000.0x | 0.00-0.2x | 0.18 | N/A | N/A |
| FCF Margin | N/A | N/A | N/A | -148.7% | -1315.4% | -606.1% | -287.3% | -52.5%-97.7pp | 45.1% | -1267.0% | N/A | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Avalo Therapeutics Inc Ranks
Frequently Asked Questions
What is Avalo Therapeutics Inc's annual revenue?
Avalo Therapeutics Inc (AVTX) reported $59K in total revenue for fiscal year 2025. This represents a -86.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Avalo Therapeutics Inc's revenue growing?
Avalo Therapeutics Inc (AVTX) revenue declined by 86.6% year-over-year, from $441K to $59K in fiscal year 2025.
Is Avalo Therapeutics Inc profitable?
No, Avalo Therapeutics Inc (AVTX) reported a net income of -$78.3M in fiscal year 2025.
What is Avalo Therapeutics Inc's EBITDA?
Avalo Therapeutics Inc (AVTX) had EBITDA of -$72.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Avalo Therapeutics Inc's return on equity (ROE)?
Avalo Therapeutics Inc (AVTX) has a return on equity of -94.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Avalo Therapeutics Inc's operating cash flow?
Avalo Therapeutics Inc (AVTX) recorded an outflow of $51.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Avalo Therapeutics Inc's total assets?
Avalo Therapeutics Inc (AVTX) had $116.5M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Avalo Therapeutics Inc spend on research and development?
Avalo Therapeutics Inc (AVTX) invested $50.1M in research and development during fiscal year 2025.
What is Avalo Therapeutics Inc's current ratio?
Avalo Therapeutics Inc (AVTX) had a current ratio of 8.14 as of fiscal year 2025, which is generally considered healthy.
What is Avalo Therapeutics Inc's debt-to-equity ratio?
Avalo Therapeutics Inc (AVTX) had a debt-to-equity ratio of 0.40 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Avalo Therapeutics Inc's return on assets (ROA)?
Avalo Therapeutics Inc (AVTX) had a return on assets of -67.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Avalo Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Avalo Therapeutics Inc (AVTX) had $15.9M in cash against an annual operating cash burn of $51.5M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Avalo Therapeutics Inc's Altman Z-Score?
Avalo Therapeutics Inc (AVTX) has an Altman Z-Score of 13.48, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Avalo Therapeutics Inc's Piotroski F-Score?
Avalo Therapeutics Inc (AVTX) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Avalo Therapeutics Inc's earnings high quality?
Avalo Therapeutics Inc (AVTX) reported a net loss of $78.3M while operations used $51.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.